Building a medtech brand?
We run PR and public affairs for companies in this market: from category launches and funding announcements to NHS procurement and regulatory communications.
Concr
Cancer treatment-response prediction
Health data & AI platforms
London/Cambridge techbio company applying astrophysics-derived modelling, its FarrSight platform, to predict how cancer patients will respond to treatment and simulate clinical trials.
The read
Concr's FarrSight platform applies modelling techniques originally developed for astrophysics to predict how individual cancer patients will respond to treatment and to simulate clinical trial outcomes, aiming to help pharma sponsors design better-targeted oncology trials.
The company has continued winning grant funding and launching new trial work into 2026, including a triple-negative breast cancer biomarker programme and its VISION clinical trial, evidence of an active, if still early-stage, research pipeline.
The Bridgehead view
Concr's astrophysics-to-oncology framing is genuinely unusual in a category otherwise dominated by conventional machine-learning pitches, and that scientific distinctiveness is worth leading with rather than burying under a standard funding-round narrative.
Work with us
Working across the healthcare sector?
We advise NHS-facing organisations, providers and health systems on reputation, policy engagement and communications that understand the sector.
The firm that knows medtech
We map this sector because
we represent it.
Whether you build medical technology or run the health systems that buy it, we know the market, the media and the regulatory landscape it operates in. Thirty minutes with a partner tells you if we can help.
